Abstract
Accumulation of intraneuronal amyloid-β peptide (Aβ) appears to be an early event in Alzheimer's disease (AD), suggesting its important role in the neurodegenerative process of AD. It is indicated that intracellular Aβ originates from a portion of Aβ, which is not secreted and consequently remains intracellular, or alternatively from the secreted Aβ, which is internalized into intracellular Aβ pool. A number of cell and transgenic animal models are established to study the pathological role of intracellular Aβ, and to screen for drugs against Aβ aggregation and associated toxicity. Aβ aggregates, particularly oligomers, may lead to synaptic dysfunction and neuronal loss. Screened from high-throughput methods, a number of cellpermeable agents reduce the aggregation of intracellular Aβ and antagonize its cytotoxicity by inhibiting the formation of Aβ oligomers in vivo. The multi-functional roles of Aβ in alternate pathways and associated clinical implications for AD treatment are also discussed.
Keywords: Alzheimer’s disease, aggregation, animal models, cell models, intracellular Aβ, oligomers, neurotoxicity, synaptic dysfunction.
Current Alzheimer Research
Title:Intracellular Aβ and its Pathological Role in Alzheimer’s Disease: Lessons from Cellular to Animal Models
Volume: 13 Issue: 6
Author(s): Lina Ji, Xi Zhao, Weijie Lu, Qing Zhang and Zichun Hua
Affiliation:
Keywords: Alzheimer’s disease, aggregation, animal models, cell models, intracellular Aβ, oligomers, neurotoxicity, synaptic dysfunction.
Abstract: Accumulation of intraneuronal amyloid-β peptide (Aβ) appears to be an early event in Alzheimer's disease (AD), suggesting its important role in the neurodegenerative process of AD. It is indicated that intracellular Aβ originates from a portion of Aβ, which is not secreted and consequently remains intracellular, or alternatively from the secreted Aβ, which is internalized into intracellular Aβ pool. A number of cell and transgenic animal models are established to study the pathological role of intracellular Aβ, and to screen for drugs against Aβ aggregation and associated toxicity. Aβ aggregates, particularly oligomers, may lead to synaptic dysfunction and neuronal loss. Screened from high-throughput methods, a number of cellpermeable agents reduce the aggregation of intracellular Aβ and antagonize its cytotoxicity by inhibiting the formation of Aβ oligomers in vivo. The multi-functional roles of Aβ in alternate pathways and associated clinical implications for AD treatment are also discussed.
Export Options
About this article
Cite this article as:
Ji Lina, Zhao Xi, Lu Weijie, Zhang Qing and Hua Zichun, Intracellular Aβ and its Pathological Role in Alzheimer’s Disease: Lessons from Cellular to Animal Models, Current Alzheimer Research 2016; 13 (6) . https://dx.doi.org/10.2174/1567205013666160322142226
DOI https://dx.doi.org/10.2174/1567205013666160322142226 |
Print ISSN 1567-2050 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5828 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Regional Differences in Adaptation of CNS Mu Opioid Receptors to Chronic Opioid Agonist Administration
Current Neuropharmacology Manipulation of Glycolysis in Malignant Tumors: Fantasy or Therapy?
Current Medicinal Chemistry Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate
Current Drug Delivery Therapeutic Applications of Crocus sativus L. (Saffron): A Review
The Natural Products Journal A Review on Anti-Cancer Activity of Some of the Oil-Soluble Organosulphur Compounds Against Colon Cancer
Current Traditional Medicine Reduction in Ischemic Cerebral Infarction is Mediated through Golgi Phosphoprotein 3 and Akt/mTOR Signaling Following Salvianolate Administration
Current Neurovascular Research Molecular Mechanisms of Neuronal Histamine and its Receptors in Obesity
Current Molecular Pharmacology Hunting for Peptide Substrates of Prolyl Oligopeptidase: Classical Versus Non-Classical Bioactive Peptides
CNS & Neurological Disorders - Drug Targets The Potential Role of Erythropoietin as a Pleiotropic Agent in Post-cardiac Arrest Syndrome
Current Pharmaceutical Design Gene Expression Profile Classification: A Review
Current Bioinformatics Selumetinib in Advanced Non Small Cell Lung Cancer (NSCLC) Harbouring KRAS Mutation: Endless Clinical Challenge to KRAS-mutant NSCLC.
Reviews on Recent Clinical Trials New Medical Strategies for Midgut Carcinoids
Anti-Cancer Agents in Medicinal Chemistry Chips for Brains
Current Genomics The Proline-Rich Domain and the Microtubule Binding Domain of Protein Tau Acting as RNA Binding Domains
Protein & Peptide Letters NPY Signalling Pathway in Bone Homeostasis: Y1 Receptor as a Potential Drug Target
Current Drug Targets Novel Metals and Metal Complexes as Platforms for Cancer Therapy
Current Pharmaceutical Design The Emerging Role of microRNA in Stroke
Current Topics in Medicinal Chemistry Counteracting PINK/Parkin Deficiency in the Activation of Mitophagy: A Potential Therapeutic Intervention for Parkinson’s Disease
Current Neuropharmacology Mutations of Chromatin Structure Regulating Genes in Human Malignancies
Current Protein & Peptide Science Human T-Cell Leukemia Virus Type 1: Transition from Latent Infection to Pathogenic Progression and Implications for Molecular Therapy
Current Cancer Therapy Reviews